The American Physiological Society Press Release

press release logo

APS Contact: APS Communications Office


Phone: 301.634.7209

Twitter: @APSPhysiology

New Hope for Lou: Unexplored Therapeutic Targets for ALS

Savannah, Ga. (September 3, 2015)—Amyotrophic lateral sclerosis (ALS) is a disorder in which cells of the nervous system die, leading to muscle weakness that impacts breathing, movement and other physical functions. More commonly known as Lou Gehrig’s disease, ALS has no cure, and the only approved therapy slows the progression by only a few months. In a new study to be presented at the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics, researchers from Johns Hopkins University have identified an unexplored avenue of treatment for ALS.

Endothelin (ET)-1, a small protein produced by blood vessel cells and a powerful vessel constrictor, is also produced by astrocytes, cells in the brain that studies are revealing play many roles in health and disease. ALS progression is associated with the dysfunction of astrocytes, and earlier studies have shown that ET-1 influences a number of cellular pathways implicated in ALS progression. Gene expression studies also suggest that levels of ET-1 and the receptor it binds to, ET-B, are elevated in patients with ALS.

This new study investigated whether levels of ET and its receptor, ET-B, were altered in the regions where nerve cells die in ALS. The researchers examined ALS patient-derived tissue samples and cells and a mouse model of ALS using a range of gene expression and protein measurement techniques. They found a higher level of ET-1 in astrocytes and a higher level of the ET-B receptor in nerve cells in regions affected in ALS. They also found variations in the gene sequences for ET-1 in patients with an inherited form of ALS.

“These experiments demonstrate striking abnormalities in the central nervous system endothelin system, [suggesting that] the endothelin system may represent a largely unexplored and potentially significant target for therapeutic intervention in ALS,” according to the researchers.

Lyle Ostrow, MD, PhD, assistant professor of neurology and pathology at Johns Hopkins University, will present “The Endothelin System in Amyotrophic Lateral Sclerosis (ALS)” at the poster session on Thursday, September 3, from 1 to 2:30 PM EDT in Ballroom BCDEF and as part of the symposium “Central Nervous System” on Saturday, September 5, at 9 AM EDT in Ballroom A of the Hyatt Regency Savannah.

NOTE TO JOURNALISTS: To read the full abstract or to schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209. Find more research highlights in the APS Press Room.

Physiology is the study of how molecules, cells, tissues and organs function in health and disease. Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.



Caffeine Appears To Be Beneficial In Males-But Not Females-With Lou Gehrig's Disease

Released April 17, 2009 - Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal disease that damages key neurons in the brain and spinal cord. The disease causes progressive paralysis of voluntary muscles and often death within five years of symptoms. A new study examined the effect of coffee, caffeine and chlorogenic acid supplementation on markers of oxidative stress, antioxidant enzyme protein content, and cell death in male and female mice models of ALS.

Leading Expert Examines Status, Promise of Key Human Protein - Endothelin - at APS Conference

Released September 10, 2009 - As the scientific and medical communities involved in endothelin move towards 25 years of understanding the protein, which future developments hold potential? At what risk? Do medicinal compounds look promising? These are among the topics being discussed at the American Physiological Society's 11th International Conference on Endothelin.

Endothelin-Related Drugs Benefit Patients With Pulmonary Hypertension

Released September 10, 2009 - The usefulness of endothelin drugs to treat congestive heart failure is not clear, according to Professor Matthias Barton, M.D., who provided an update on endothelin research at the American Physiological Society's 11th International Conference on Endothelin.

Males May Experience Greater Physical Pain Due to Lower Levels of Key Protein, Endothelin

Released September 10, 2009 - How vaso-occulsion leads to pain, and its impact on males and females are still unknown. A University of South Carolina research team suggests that a naturally occurring chemical in the body, endothelin, may play a role. Presentation is part of the American Physiological Society's 11th International Conference on Endothelin.